Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support.
Wolff
Antonio C
AC
Jones
Richard J
RJ
Davidson
Nancy E
NE
Jeter
Stacie C
SC
Stearns
Vered
V
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects*; D006801:Humans; D007964:Leukocytosis / Q000139:chemically induced*; D008408:Mastectomy; D009196:Myeloproliferative Disorders / Q000139:chemically induced; D009503:Neutropenia / Q000139:chemically induced; D011092:Polyethylene Glycols; D011878:Radiotherapy; D011994:Recombinant Proteins; D043823:Taxoids / Q000008:administration & dosage
D011994:Recombinant Proteins; D043823:Taxoids; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D000069585:Filgrastim